BACKGROUND: The natriuretic peptides are counterregulatory hormones involved in volume homeostasis and cardiovascular remodeling. The prognostic significance of plasma natriuretic peptide levels in apparently asymptomatic persons has not been established. METHODS: We prospectively studied 3346 persons without heart failure. Using proportional-hazards regression, we examined the relations of plasma B-type natriuretic peptide and N-terminal pro-atrial natriuretic peptide to the risk of death from any cause, a first major cardiovascular event, heart failure, atrial fibrillation, stroke or transient ischemic attack, and coronary heart disease. RESULTS: During a mean follow-up of 5.2 years, 119 participants died and 79 had a first cardiovascular event. After adjustment for cardiovascular risk factors, each increment of 1 SD in log B-type natriuretic peptide levels was associated with a 27 percent increase in the risk of death (P=0.009), a 28 percent increase in the risk of a first cardiovascular event (P=0.03), a 77 percent increase in the risk of heart failure (P<0.001), a 66 percent increase in the risk of atrial fibrillation (P<0.001), and a 53 percent increase in the risk of stroke or transient ischemic attack (P=0.002). Peptide levels were not significantly associated with the risk of coronary heart disease events. B-type natriuretic peptide values above the 80th percentile (20.0 pg per milliliter for men and 23.3 pg per milliliter for women) were associated with multivariable-adjusted hazard ratios of 1.62 for death (P=0.02), 1.76 for a first major cardiovascular event (P=0.03), 1.91 for atrial fibrillation (P=0.02), 1.99 for stroke or transient ischemic attack (P=0.02), and 3.07 for heart failure (P=0.002). Similar results were obtained for N-terminal pro-atrial natriuretic peptide. CONCLUSIONS: In this community-based sample, plasma natriuretic peptide levels predicted the risk of death and cardiovascular events after adjustment for traditional risk factors. Excess risk was apparent at natriuretic peptide levels well below current thresholds used to diagnose heart failure. Copyright 2004 Massachusetts Medical Society
BACKGROUND: The natriuretic peptides are counterregulatory hormones involved in volume homeostasis and cardiovascular remodeling. The prognostic significance of plasma natriuretic peptide levels in apparently asymptomatic persons has not been established. METHODS: We prospectively studied 3346 persons without heart failure. Using proportional-hazards regression, we examined the relations of plasma B-type natriuretic peptide and N-terminal pro-atrial natriuretic peptide to the risk of death from any cause, a first major cardiovascular event, heart failure, atrial fibrillation, stroke or transient ischemic attack, and coronary heart disease. RESULTS: During a mean follow-up of 5.2 years, 119 participants died and 79 had a first cardiovascular event. After adjustment for cardiovascular risk factors, each increment of 1 SD in log B-type natriuretic peptide levels was associated with a 27 percent increase in the risk of death (P=0.009), a 28 percent increase in the risk of a first cardiovascular event (P=0.03), a 77 percent increase in the risk of heart failure (P<0.001), a 66 percent increase in the risk of atrial fibrillation (P<0.001), and a 53 percent increase in the risk of stroke or transient ischemic attack (P=0.002). Peptide levels were not significantly associated with the risk of coronary heart disease events. B-type natriuretic peptide values above the 80th percentile (20.0 pg per milliliter for men and 23.3 pg per milliliter for women) were associated with multivariable-adjusted hazard ratios of 1.62 for death (P=0.02), 1.76 for a first major cardiovascular event (P=0.03), 1.91 for atrial fibrillation (P=0.02), 1.99 for stroke or transient ischemic attack (P=0.02), and 3.07 for heart failure (P=0.002). Similar results were obtained for N-terminal pro-atrial natriuretic peptide. CONCLUSIONS: In this community-based sample, plasma natriuretic peptide levels predicted the risk of death and cardiovascular events after adjustment for traditional risk factors. Excess risk was apparent at natriuretic peptide levels well below current thresholds used to diagnose heart failure. Copyright 2004 Massachusetts Medical Society
Authors: Alain G Bertoni; Lynne E Wagenknecht; Dalane W Kitzman; Santica M Marcovina; Julia T Rushing; Mark A Espeland Journal: Obesity (Silver Spring) Date: 2011-09-29 Impact factor: 5.002
Authors: Susan Cheng; Martin G Larson; Michelle J Keyes; Elizabeth L McCabe; Christopher Newton-Cheh; Daniel Levy; Emelia J Benjamin; Ramachandran S Vasan; Thomas J Wang Journal: Am J Cardiol Date: 2010-07-23 Impact factor: 2.778
Authors: J Gustav Smith; Christopher Newton-Cheh; Peter Almgren; Joachim Struck; Nils G Morgenthaler; Andreas Bergmann; Pyotr G Platonov; Bo Hedblad; Gunnar Engström; Thomas J Wang; Olle Melander Journal: J Am Coll Cardiol Date: 2010-11-16 Impact factor: 24.094
Authors: Eui-Young Choi; Hossein Bahrami; Colin O Wu; Philip Greenland; Mary Cushman; Lori B Daniels; Andre L C Almeida; Kihei Yoneyama; Anders Opdahl; Aditya Jain; Michael H Criqui; David Siscovick; Christine Darwin; Alan Maisel; David A Bluemke; Joao A C Lima Journal: Circ Heart Fail Date: 2012-10-02 Impact factor: 8.790
Authors: Paul M McKie; Richard J Rodeheffer; Alessandro Cataliotti; Fernando L Martin; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Margaret M Redfield; John C Burnett Journal: Hypertension Date: 2006-04-03 Impact factor: 10.190
Authors: Xiaoyan Yin; Subha Subramanian; Shih-Jen Hwang; Christopher J O'Donnell; Caroline S Fox; Paul Courchesne; Pieter Muntendam; Neal Gordon; Aram Adourian; Peter Juhasz; Martin G Larson; Daniel Levy Journal: Arterioscler Thromb Vasc Biol Date: 2014-02-13 Impact factor: 8.311
Authors: Aaron R Folsom; Pamela L Lutsey; Vijay Nambi; Christopher R deFilippi; Susan R Heckbert; Mary Cushman; Christie M Ballantyne Journal: Vasc Med Date: 2014-02 Impact factor: 3.239